These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 1098350)

  • 1. Testosterone undecanoate: a new orally active androgen.
    Hirschhäuser C; Hopkinson CR; Sturm G; Coert A
    Acta Endocrinol (Copenh); 1975 Sep; 80(1):179-87. PubMed ID: 1098350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma androgens after a single oral dose of testosterone undecanoate.
    Geere G; Jones J; Atherden SM; Grant DB
    Arch Dis Child; 1980 Mar; 55(3):218-20. PubMed ID: 7387164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reexamination of pharmacokinetics of oral testosterone undecanoate in hypogonadal men with a new self-emulsifying formulation.
    Yin AY; Htun M; Swerdloff RS; Diaz-Arjonilla M; Dudley RE; Faulkner S; Bross R; Leung A; Baravarian S; Hull L; Longstreth JA; Kulback S; Flippo G; Wang C
    J Androl; 2012; 33(2):190-201. PubMed ID: 21474786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men.
    Jockenhövel F; Bullmann C; Schubert M; Vogel E; Reinhardt W; Reinwein D; Müller-Wieland D; Krone W
    Metabolism; 1999 May; 48(5):590-6. PubMed ID: 10337859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A ten-year safety study of the oral androgen testosterone undecanoate.
    Gooren LJ
    J Androl; 1994; 15(3):212-5. PubMed ID: 7928661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypogonadal men treated with oral testosterone undecanoate.
    Sarris S; Swyer GI; Lawrence DM
    Acta Eur Fertil; 1977 Dec; 8(4):297-9. PubMed ID: 610314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Which testosterone replacement therapy?
    Cantrill JA; Dewis P; Large DM; Newman M; Anderson DC
    Clin Endocrinol (Oxf); 1984 Aug; 21(2):97-107. PubMed ID: 6467640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen levels and sex functions in testosterone-treated hypogonadal men.
    Gooren LJ
    Arch Sex Behav; 1987 Dec; 16(6):463-73. PubMed ID: 3426390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism.
    Meuleman EJ; Legros JJ; Bouloux PM; Johnson-Levonas AO; Kaspers MJ; Elbers JM; Geurts TB; Meehan AG;
    Aging Male; 2015; 18(3):157-63. PubMed ID: 26030346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoate.
    Yassin AA; Saad F
    Andrologia; 2007 Oct; 39(5):181-4. PubMed ID: 17714216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accurate measurement of androgen after androgen esters: problems created by ex vivo esterase effects and LC-MS/MS interference.
    Ceponis J; Swerdloff R; Leung A; Hull L; Bai F; Longstreth J; Dudley R; Danoff T; Wang C
    Andrology; 2019 Jan; 7(1):42-52. PubMed ID: 30345711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary fat modulates the testosterone pharmacokinetics of a new self-emulsifying formulation of oral testosterone undecanoate in hypogonadal men.
    Yin A; Alfadhli E; Htun M; Dudley R; Faulkner S; Hull L; Leung A; Bross R; Longstreth J; Swerdloff R; Wang C
    J Androl; 2012; 33(6):1282-90. PubMed ID: 22790645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study.
    Skakkebaek NE; Bancroft J; Davidson DW; Warner P
    Clin Endocrinol (Oxf); 1981 Jan; 14(1):49-61. PubMed ID: 7014044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
    J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men.
    Nieschlag E; Büchter D; Von Eckardstein S; Abshagen K; Simoni M; Behre HM
    Clin Endocrinol (Oxf); 1999 Dec; 51(6):757-63. PubMed ID: 10619981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacology and metabolism of testosterone undecanoate (TU), a new orally active androgen.
    Coert A; Geelen J; de Visser J; van der Vies J
    Acta Endocrinol (Copenh); 1975 Aug; 79(4):789-800. PubMed ID: 1173974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of various modes of androgen substitution therapy on erythropoiesis.
    Jockenhövel F; Vogel E; Reinhardt W; Reinwein D
    Eur J Med Res; 1997 Jul; 2(7):293-8. PubMed ID: 9233903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of testosterone undecanoate in male hypogonadism.
    Maisey NM; Bingham J; Marks V; English J; Chakraborty J
    Clin Endocrinol (Oxf); 1981 Jun; 14(6):625-9. PubMed ID: 7296909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men.
    Swerdloff RS; Wang C; White WB; Kaminetsky J; Gittelman MC; Longstreth JA; Dudley RE; Danoff TM
    J Clin Endocrinol Metab; 2020 Aug; 105(8):2515-31. PubMed ID: 32382745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgens, behaviour and nocturnal erection in hypogonadal men: the effects of varying the replacement dose.
    O'Carroll R; Shapiro C; Bancroft J
    Clin Endocrinol (Oxf); 1985 Nov; 23(5):527-38. PubMed ID: 3910302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.